Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
11:45am, Wednesday, 26'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:R
Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc.(REGN) of a Class Action Lawsuit and an Upcoming Deadline
10:30am, Wednesday, 26'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
10:00am, Wednesday, 26'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceutical
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Re
Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
07:00am, Wednesday, 26'th Feb 2025
TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmiss
Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
03:05am, Wednesday, 26'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN
06:30pm, Tuesday, 25'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
REGN Deadline: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
05:00pm, Tuesday, 25'th Feb 2025
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
04:38pm, Tuesday, 25'th Feb 2025
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such
Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)
06:30pm, Monday, 24'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between N
